Please login to the form below

Not currently logged in


This page shows the latest Anacor news and features for those working in and with pharma, biotech and healthcare.

Pfizer mulling product sale to streamline ops; sources

Pfizer mulling product sale to streamline ops; sources

The company bought Medivation and Anacor last year - for $14bn and $5.2bn respectively - after previously failing to bring mega-mergers with AstraZeneca and Allergan to fruition. ... The Medivation deal brought in prostate cancer treatment Xtandi

Latest news

  • FDA green light for Pfizer's eczema drug FDA green light for Pfizer's eczema drug

    It needs the drug to perform as expected, having paid $5.2bn for the drug's originator Anacor in May.

  • LEO Pharma picks up AZ skin disease drugs in $1bn deal LEO Pharma picks up AZ skin disease drugs in $1bn deal

    Should the two drugs meet with regulatory approval, tralokinumab will potentially face Anacor's eczema drug crisaborole, which has recently been bought by Pfizer, and is currently under review by the

  • Pfizer adds eczema drug with $5.2bn Anacor acquisition Pfizer adds eczema drug with $5.2bn Anacor acquisition

    Expands innovative products business with non-steroidal therapy Crisaborole. Pfizer has snapped up Californian biopharma company Anacor in a $5.2bn deal that gives it a late-stage eczema candidate. ... Anacor's eczema drug - a topical gel formulation of

  • Biologics buoyant

    In the small molecule area, GSK has paid $15m to exercise its option for an exclusive licence to develop and commercialise a novel, systemic antibiotic derived from Anacor's boron chemistry ... Discovery platform . 139. Anacor/GSK. GSK '052 –

  • GSK and Anacor in systemic anti-infective tie-up

    As a result, GSK now has access to Anacor's proprietary boron-based chemistry for use against selected targets. ... Anacor will receive a USD 12m upfront payment and a USD 10m equity financing commitment from GSK.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    It seems Pfizer has got the message judging from the Anacor acquisition for $5.2bn in May and a hat trick of deals this month, including the acquisitions of Medivation for

  • Deal Watch May 2016 Deal Watch May 2016

    Topping this month's DW table with a headline value of $5.2bn is Pfizer's takeover of Anacor Pharmaceuticals which exemplifies this trend. ... Licensor/ Acquired Acquirer/ Partner. Deal Type. Comments. Headline $m. Anacor/ Pfizer.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    202+. Aciex Therapeutics/ NicOx. Company acquisition. Portfolio of ophthalmic products, inc AC-170 for allergic conjunctivitis (p3)    . 120. Anacor Pharmaceuticals/ PharmaDerm (Sandoz). Licence†. Kerydin topical for toenail onychomycosis

  • Pharma deals during October 2013 Pharma deals during October 2013

    This became the source of a dispute when Valeant intended launching its own product Jublia (efinaconazole) for the same indication; Anacor then initiated arbitration proceedings last year. ... However, Anacor had sought an award of at least $215m plus

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    XEN-D103 ion channel modulator for atrial fibrillation (phase I). 162.4. Anacor / Valeant.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....